P02.186. CAST (Centella asiatica selected triterpenes): stability, safety, and effect on diabetic neuropathy (DN)

Soumyanath, Amala; Dimitrova, Dessislava; Arnold, G.; Belding, Heather; Seifer, Nick; Le, Ngoc Anh; Lou, Jau‐Shin

doi:10.1186/1472-6882-12-s1-p242

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dynamic properties of the cell cortex and its actin cytoskeleton determine important aspects of cell behavior and are a major target of cell regulation. The expression of Marcks has been found to be locally abundant and to correlate with morpho-genic processes and cell motility, and the protein accumulates at plasmalemmal rafts, where it is co-distributed with PI( 4 , 5 ) P( 2 ) and promotes its retention and clustering ( 25 ). DN is the most common cause of end-stage renal disease (ESRD) among type 2 diabetes mellitus patients (DM) in Malaysia ( 26 ).…”

Section: Discussionmentioning

confidence: 99%

“…The accurate and timely detection, characterization and quantification of DN are critical for the identification of patients at risk, the estimation of expected deterioration, the monitoring of progression, the assessment of novel therapies, and, ultimately, for the reduction of the incidence and cost of treatment for this disease. Current treatments for DN provide symptomatic relief rather than ameliorating disease progression ( 4 ). A previous clinical study on type II diabetes demonstrated that the insulin sensitizer rosiglitazone (Rosi) (Avandia), a synthetic agonist of peroxisome proliferator-activated receptor-γ (PPAR-γ) that is used to improve insulin resistance, is a potential drug for the treatment of DN ( 5 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gene expression microarray analysis of the sciatic nerve of mice with diabetic neuropathy

Zhang

Liang

et al. 2014

International Journal of Molecular Medicine

View full text Add to dashboard Cite

The present study aimed to explore novel target genes that regulate the development of diabetic neuropathy (DN) by analyzing gene expression profiles in the sciatic nerve of infected mice. The GSE11343 microarray dataset, which was downloaded from Gene Expression Omnibus, included data on 4 control samples and 5 samples from mice with diabetes induced by streptozotocin (STZ), 5 samples from normal mice treated with rosiglitazone (Rosi) and 5 samples from mice with diabetes induced by STZ and treated with Rosi. Differentially expressed genes (DEGs) between the different groups were identified using the substitution augmentation modification redefinition (SAMR) model. The Gene Ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID). Regulatory and protein-protein interaction networks were searched using BioCarta and STRING, respectively. The protein structures of potential regulatory genes were predicted using the SYBYL program. Compared with the controls, 1,384 DEGs were identified in the mice with STZ-induced diabetes and 7 DEGs were identified in the mice treated with Rosi. There were 518 DEGs identified between the mice in the STZ + Rosi and STZ groups. We identified 45 GO items, and the calmodulin nerve phosphatase and chemokine signaling pathways were identified as the main pathways. Three genes [myristoylated alanine-rich protein kinase C substrate (Marcks), GLI pathogenesis-related 2 (Glipr2) and centrosomal protein 170 kDa (Cep170)] were found to be co-regulated by both STZ and Rosi, the protein structure of which was predicted and certain binding activity to Rosi was docked. Our study demonstrates that the Marcks, Glipr2 and Cep170 genes may be underlying drug targets in the treatment of DN.

show abstract